Aptevo Therapeutics APVO 深 沪
等待开盘 09-25 09:30:00 美东时间
1.78
+0.140
+8.54%
华盛通- 最 高1.8302
- 今 开1.61
- 成交量 273.73万股
- 最 低 1.605
- 昨 收 1.64
- 总市值 585.25万
- 52周最高 381.10
- 市盈率 静 --
- 换手率 83.25%
- 52周最低 1.32
- 委 比 -93.28%
- 总股本 328.79万
- 历史最高 3778913.60
- 量 比 0.10
- 振 幅 13.73%
- 历史最低 1.605
- 每 手 1
- 风险率 69.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for September 18th
INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Intel's Stock At $23.28 Per Share NVO: 7% | Novo Nordisk Announced Ozempic Reduces
09-18 19:21
Aptevo Announces 100% Remission in AML Trial
Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On September 16,...
09-17 05:30
Aptevo's Mipletamig Achieves 100% Remission With Favorable Safety In Phase 1b/2 AML Trial; Cohort 4 Now Open For Enrollment
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerabilityTrial progressing efficiently, Cohort 4 open for enrollmentSEATTLE, WA
09-16 20:33
Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive
09-04 20:50
Aptevo Unveils APVO442 Precision CD3 Bispecific For Prostate Cancer, Advancing Solid Tumor Strategy With CRIS-7 Platform
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3
08-13 20:14
Aptevo Therapeutics Q2 EPS $(8.40) Beats $(83.20) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(8.40) per share which beat the analyst consensus estimate of $(83.20) by 89.9 percent. This is a 99.32 percent increase over losses of $(1.24 thousand) per
08-11 20:10
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance
Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. In response to a...
07-01 04:59
Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
06-21 20:00
Aptevo Therapeutics Raises $7.45M Through Stock Sale
Aptevo Therapeutics ( ($APVO) ) has shared an update. On June 18, 2025, Aptevo ...
06-21 04:41
